<  Retour au portail Polytechnique Montréal

Documents publiés en "2022"

Monter d'un niveau
Pour citer ou exporter [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Grouper par: Auteurs ou autrices | Département | Sous-type de document | Aucun groupement
Aller à : G | L | M
Nombre de documents: 4

G

Grajales, D., Kadoury, S., Shams, R., Barkati, M., Delouya, G., Béliveau-Nadeau, D., Nicolas, B., Le, W. T., Benhacene-Boudam, M.-K., Juneau, D., DaSilva, J. N., Carrier, J.-F., Hautvast, G., & Ménard, C. (2022). Performance of an integrated multimodality image guidance and dose-planning system supporting tumor-targeted HDR brachytherapy for prostate cancer. Radiotherapy and Oncology, 166, 154-161. Lien externe

L

Lopera, D. O. G., Picot, F., Shams, R., Dallaire, F., Sheehy, G., Alley, S., Barkati, M., Delouya, G., Carrier, J.-F., Birlea, M., Trudel, D., Leblond, F., Menard, C., & Kadoury, S. (2022). Image-guided Raman spectroscopy navigation system to improve transperineal prostate cancer detection. Part 2: in-vivo tumor-targeting using a classification model combining spectral and MRI-radiomics features. Journal of Biomedical Optics, 27(9), 095004 (16 pages). Lien externe

M

Ménard, C., Navarro-Domenech, I., Liu, Z., Joseph, L., Barkati, M., Berlin, A., Delouya, G., Taussky, D., Beauchemin, M.-C., Nicolas, B., Kadoury, S., Rink, A., Raman, S., Sundaramurthy, A., Weersink, R., Béliveau-Nadeau, D., Helou, J., & Chun, P. (2022). Corrigendum: MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer. Frontiers in Oncology, 12, 2 pages. Lien externe

Ménard, C., Navarro-Domenech, I., Liu, Z., Joseph, L., Barkati, M., Berlin, A., Delouya, G., Taussky, D., Beauchemin, M.-C., Nicolas, B., Kadoury, S., Rink, A., Raman, S., Sundaramurthy, A., Weersink, R., Béliveau-Nadeau, D., Helou, J., & Chun, P. (2022). MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer. Frontiers in Oncology, 12, 971344 (9 pages). Lien externe

Liste produite: Sun Dec 29 01:54:43 2024 EST.